X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1037) 1037
beta-alanine - analogs & derivatives (920) 920
dabigatran (721) 721
male (600) 600
beta-alanine - administration & dosage (525) 525
female (396) 396
benzimidazoles - administration & dosage (379) 379
beta-alanine - therapeutic use (378) 378
benzimidazoles - therapeutic use (358) 358
beta-alanine - adverse effects (352) 352
rivaroxaban (344) 344
benzimidazoles - adverse effects (341) 341
administration, oral (325) 325
warfarin (318) 318
animals (317) 317
anticoagulants - administration & dosage (290) 290
atrial fibrillation - drug therapy (276) 276
anticoagulants - therapeutic use (269) 269
aged (263) 263
anticoagulants (253) 253
stroke - prevention & control (236) 236
anticoagulants - adverse effects (227) 227
beta-alanine - pharmacology (225) 225
atrial fibrillation (216) 216
middle aged (201) 201
thiophenes - therapeutic use (195) 195
morpholines - therapeutic use (194) 194
hemorrhage - chemically induced (176) 176
atrial fibrillation - complications (172) 172
rats (162) 162
pyridones - therapeutic use (159) 159
treatment outcome (159) 159
pyrazoles - therapeutic use (158) 158
stroke (158) 158
dabigatran etexilate (156) 156
beta-alanine (154) 154
morpholines - administration & dosage (150) 150
thiophenes - administration & dosage (150) 150
antithrombins - administration & dosage (149) 149
antithrombins - adverse effects (146) 146
adult (145) 145
cardiac & cardiovascular systems (144) 144
warfarin - therapeutic use (138) 138
abridged index medicus (137) 137
dietary supplements (136) 136
atrial-fibrillation (131) 131
peripheral vascular disease (126) 126
aged, 80 and over (122) 122
hematology (122) 122
venous thromboembolism (122) 122
stroke - etiology (121) 121
medicine, general & internal (120) 120
morpholines - adverse effects (120) 120
risk factors (120) 120
thiophenes - adverse effects (120) 120
prevention (118) 118
pharmacology & pharmacy (117) 117
warfarin - administration & dosage (115) 115
pyrazoles - administration & dosage (112) 112
dose-response relationship, drug (111) 111
pyridones - administration & dosage (110) 110
etexilate (109) 109
antithrombins - therapeutic use (108) 108
apixaban (108) 108
thrombin (104) 104
beta-alanine - pharmacokinetics (102) 102
direct thrombin inhibitor (100) 100
drug therapy (99) 99
warfarin - adverse effects (97) 97
anticoagulation (93) 93
biochemistry & molecular biology (91) 91
thromboembolism - prevention & control (91) 91
carnosine (90) 90
mice (87) 87
sport sciences (87) 87
pyrazoles - adverse effects (85) 85
pyridones - adverse effects (84) 84
pharmacokinetics (82) 82
exercise (81) 81
risk (81) 81
stroke prevention (76) 76
therapy (75) 75
time factors (75) 75
thromboembolism (73) 73
randomized controlled trials as topic (71) 71
analysis (70) 70
management (70) 70
amino acids (69) 69
medicine & public health (69) 69
blood coagulation - drug effects (68) 68
metabolism (68) 68
care and treatment (66) 66
research (66) 66
young adult (66) 66
benzimidazoles - pharmacokinetics (64) 64
benzimidazoles - pharmacology (64) 64
beta-alanine - blood (64) 64
factor xa inhibitors (64) 64
health aspects (64) 64
nutrition & dietetics (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1219) 1219
Japanese (55) 55
German (23) 23
French (15) 15
Spanish (14) 14
Russian (13) 13
Hungarian (4) 4
Danish (3) 3
Italian (3) 3
Czech (2) 2
Portuguese (2) 2
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
Norwegian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Stroke (1970), ISSN 1524-4628, 2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in... 
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | SURGERY | DIRECT THROMBIN INHIBITOR | FONDAPARINUX | oral anticoagulant | PREVENTION | DEEP-VEIN THROMBOSIS | prophylaxis | total hip arthroplasty | KNEE REPLACEMENT | venous thromboembolism | MOLECULAR-WEIGHT HEPARIN | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
Thrombosis Research, ISSN 0049-3848, 2014, Volume 134, Issue 4, pp. 774 - 782
...) between 2.0 and 3.0]. LMWH are effective and safe also for the long-term treatment of VTE. However, they still require daily parenteral subcutaneous (SC) administration... 
Hematology, Oncology and Palliative Medicine | Rivaroxaban | Warfarin | Dabigatran | Edoxaban | Venous thromboembolism | Apixaban | XA INHIBITOR RIVAROXABAN | EFFICACY | SAFETY | DEEP-VEIN THROMBOSIS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Thiazoles - administration & dosage | Thiophenes - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Venous Thromboembolism - drug therapy | Pyridones - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | beta-Alanine - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Animals | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Analysis
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2013, Volume 26, Issue 2, pp. 191 - 202
In the past decade, several new oral anticoagulants (NOACs) have been studied and approved for the prophylaxis and treatment of arterial and venous... 
Hematology, Oncology and Palliative Medicine | dabigatran | reversal | rivaroxaban | bleeding | apixaban | edoxaban | bleeding reversal | DIRECT THROMBIN INHIBITOR | RECOMBINANT FACTOR VIIA | RANDOMIZED EVALUATION | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | HEMOSTATIC THERAPY | HEMATOLOGY | FACTOR XA INHIBITOR | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Thiazoles - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Thiazoles - adverse effects | Pyridones - administration & dosage | Rivaroxaban | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Thromboembolism - drug therapy | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Thromboembolism - pathology | Pyrazoles - adverse effects | beta-Alanine - adverse effects | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Prothrombin - analogs & derivatives | Prothrombin - therapeutic use | Anticoagulants - adverse effects | Randomized Controlled Trials as Topic | Pyrazoles - administration & dosage | Blood Coagulation Factors - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Hemorrhage - pathology | Pyridones - adverse effects | Monoclonal antibodies | Thrombin | Warfarin | Thromboembolism | Farmakologi och toxikologi | Hematologi | Klinisk medicin | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2013, Volume 29, Issue 7, pp. S24 - S33
Abstract Warfarin has been the mainstay oral anticoagulant (OAC) medication prescribed for stroke prevention in atrial fibrillation (AF) patients. However,... 
Cardiovascular | IN-VITRO | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | VENOUS THROMBOEMBOLISM | STROKE PREVENTION | ASSAYS LABORATORY RECOMMENDATIONS | ORAL BIOAVAILABILITY | NONVALVULAR ATRIAL-FIBRILLATION | COAGULATION ASSAYS | Anticoagulants - administration & dosage | Outcome Assessment (Health Care) | Thiophenes - adverse effects | Humans | beta-Alanine - pharmacokinetics | Warfarin - adverse effects | Biological Availability | Thiophenes - administration & dosage | Dabigatran | Drug Monitoring - methods | Warfarin - administration & dosage | Patient Selection | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Drug Interactions | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Pyrazoles - pharmacokinetics | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Stroke - prevention & control | beta-Alanine - adverse effects | Pyridones - pharmacokinetics | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Polymorphism, Genetic | Warfarin - pharmacokinetics | Atrial Fibrillation - blood | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Stroke - etiology | Blood Coagulation - drug effects | Blood Coagulation - genetics | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Pyridones - adverse effects
Journal Article
European Journal of Vascular & Endovascular Surgery, ISSN 1078-5884, 2014, Volume 48, Issue 5, pp. 565 - 575
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2014, Volume 111, Issue 4, pp. 575 - 582
During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and on treatment of venous thromboembolism have been completed for... 
thrombin inhibitor | Atrial fibrillation | venous thromboembolism | Xa inhibitor | Theme Issue Article | Thrombin inhibitor | Venous thromboembolism | DIRECT THROMBIN INHIBITOR | STROKE PREVENTION | RIVAROXABAN | OPEN-LABEL | RANDOMIZED EVALUATION | APIXABAN | ATRIAL-FIBRILLATION | atrial fibrillation | THERAPY | DABIGATRAN ETEXILATE | WARFARIN | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Thiophenes - adverse effects | Humans | Warfarin - adverse effects | Risk | Thiazoles - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Thiazoles - adverse effects | Venous Thromboembolism - drug therapy | Patient Selection | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Venous Thromboembolism - complications | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Stroke - prevention & control | beta-Alanine - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Treatment Outcome | Pyrazoles - administration & dosage | Pyridones - adverse effects
Journal Article
Journal Article